This is a ready-to-use risk assessment for evaluating a proposed change to a validated analytical procedure against its documented proven acceptable range (PAR) or method operable design region (MODR). It exists because “is the method different” is the wrong question; the question a defensible change decision has to answer is whether the change stays inside understood territory and whether the changed method still meets its Analytical Target Profile (ATP). This assessment is distinct from a generic computerized-system or equipment change risk assessment: it is scoped specifically to the analytical-method-lifecycle boundary question ICH Q14 introduces. Replace every <<FILL: ...>> placeholder with your own specifics. A worked filled specimen follows the template. Verify each cited regulation against the current source before you rely on it.
1. Purpose
This assessment evaluates a proposed change to a validated analytical procedure and classifies it into a handling path, verification-only, partial or full revalidation, or treatment as a new procedure, based on whether the change stays inside a documented proven acceptable range or MODR and whether it changes the underlying measurement principle. It exists so the handling decision is traceable to the development understanding rather than to an unstated judgment call about how “big” the change feels.
2. Scope
This assessment covers a single proposed change to the method named above. It does not itself execute the confirmatory testing it may call for; it decides what testing is required and at what depth. It does not set the regulatory reporting category on its own; section 8 feeds that decision but the applicable regional variation or supplement framework and any ICH Q12 established conditions govern the final filing action.
3. Responsibilities
4. Methodology
The classification is a two-axis decision, not a single severity score. Axis 1 asks whether the changed parameter(s) fall inside a range the development report already studied. Axis 2 asks whether the change alters the measurement principle itself (for example, detection chemistry, separation mode, or assay format) rather than a parameter within an unchanged principle. The two axes combine into a handling path in section 6. This mirrors, and gives documented, repeatable structure to, the change-control decision logic in ICH Q14.
A change that fails Axis 1 (outside any studied range) but passes Axis 2 (same technique) still requires confirmatory data; it is not automatically a full revalidation, but the depth of testing is set by how far outside the studied range the change sits and what the ATP’s performance margin can absorb, assessed in section 7.
5. Scoring scale (boundary and principle status)
6. Assessment table: classification and handling path
7. Assessment for this change
8. Regulatory reporting implication
9. Mitigations
10. Residual risk and approval
References
ICH Q14, Analytical Procedure Development (proven acceptable range and MODR concepts).
ICH Q2(R2), Validation of Analytical Procedures (scope of revalidation where required).
ICH Q12, Lifecycle Management (established conditions and post-approval change management protocols).
ICH Q10, Pharmaceutical Quality System (in-PQS change handling).
Confirm the current version of each reference, and the applicable regional variation/supplement framework, before issue.
Revision history
Approvals
Filled specimen
The following shows the assessment completed for an illustrative discontinued-column change on a finished-product assay. Numbers and sources are illustrative; replace them with your own.
Section 8. Established conditions APD-EC-004 define the column stationary-phase family, not a specific supplier part number, as the established condition. Change falls within established conditions: yes. Proposed reporting category: in-PQS change, documented in the quality system, no prior-approval submission required. Regulatory affairs sign-off: T. Reyes, 12 September 2026.
Section 10. Final classification: Understood, in-PQS change. Confirmatory testing outcome: pass (comparative run report CMP-2026-041). Residual risk statement: acceptable, ATP re-confirmed by comparative testing; no further action required beyond routine trending of the new column lot.
Common inspection findings this risk assessment prevents
- A method change judged “minor” by feel, with no documented check against the studied PAR/MODR, so the classification cannot be defended later.
- A change that actually alters the measurement principle handled as an in-PQS change because the difference “seemed small,” skipping the development and validation work a new procedure requires.
- Confirmatory testing scoped without reference to the ATP’s performance margin, so a comparative run passes on a criterion that was never tied to what the ATP actually requires.
- A reporting-category decision made without checking whether the change is covered by an established condition on file, resulting in either an unnecessary submission or a missed one.
- A change repeatedly classified “Understood” for a parameter that in fact has no development data behind it, because no one checked whether a PAR was ever actually established.
How to adapt this risk assessment
- Set your document number, method, ATP, and development report references in the header.
- Confirm the studied ranges you cite in section 7 come directly from the development report, not from memory or an assumption of similarity.
- If the method was validated under the minimal approach and no PAR/MODR exists, default to the conservative “no development data exists” row in section 6 until one is established.
- Route section 8 to regulatory affairs before implementing the change, not after; established conditions determine the reporting category, and a change implemented ahead of the correct filing action is itself a finding.
- Feed a repeated pattern of “outside studied range” classifications for the same parameter back into a future development report; that pattern is a signal the original PAR was set too narrow.
